Floatz logo

HYDROMORPHON

B-Cell Lymphoma

National Cancer Institute (NCI)Small moleculePhase 2Active
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
73/ 100

Competitive context

17 Active assets in the B-Cell Lymphoma cohort.

Asset / SponsorPhaseRating
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
Mwanasha Merrill, MD
Phase 3BB
Venetoclax
Nurix Therapeutics, Inc.
Phase 2B
Clofarabine
M.D. Anderson Cancer Center
Phase 2B
LMB-C
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3B
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE
National Cancer Institute (NCI)
Phase 2CCC

View all 40 →

Same molecule, other indications

HYDROMORPHON is also rated in:

substance-related disorderDormant
BBB
Indicative ·
74 / 100
View asset →
Low Back PainDormant
BBB
Indicative ·
72 / 100
View asset →
Analgesics, OpioidDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →